Fredun Pharmaceuticals Ltd — Important, 17-08-2026: Company Update

Fredun Pharmaceuticals discussed its strong Q1 results, reporting a 90% revenue growth to INR228.25 Cr, EBITDA up 93% to INR32.78 Cr, and net profit up 95% to INR13.17 Cr. The company expects 30-35% blended annual growth for its diverse portfolio, driven by new age brands and capacity expansion. Its Fredun GX line is expanding into 19 states, targeting 25-35% yearly growth. The comprehensive pet care platform, Wagr.in, is soft-launched and adding services. CapEx for the current year is projected at INR30-40 Cr, focused on becoming a large manufacturing unit. Future margin expansion is anticipated after initial penetration efforts.